Glutamate decarboxylase deficiency

Glutamate Decarboxylase Deficiency is a rare neurological disorder characterized by a deficiency in the enzyme glutamate decarboxylase (GAD), which is crucial for the proper functioning of the nervous system. This enzyme is responsible for converting glutamate, the primary excitatory neurotransmitter in the brain, into gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter. The imbalance between excitatory and inhibitory signals in the brain leads to various neurological symptoms.

Symptoms

The symptoms of Glutamate Decarboxylase Deficiency can vary widely among affected individuals but commonly include seizures, developmental delay, hypotonia (decreased muscle tone), and ataxia (lack of muscle coordination). Some patients may also exhibit anxiety, depression, and other psychiatric symptoms due to the imbalance of neurotransmitters in the brain.

Causes

Glutamate Decarboxylase Deficiency is caused by mutations in the GAD1 gene, which encodes the 67kDa isoform of glutamate decarboxylase (GAD67). GAD67 is one of the two forms of the enzyme found in the brain, the other being GAD65, encoded by the GAD2 gene. These mutations lead to reduced activity of GAD67, resulting in decreased production of GABA and an excess of glutamate, disrupting the excitatory-inhibitory balance in the brain.

Diagnosis

Diagnosis of Glutamate Decarboxylase Deficiency involves a combination of clinical evaluation, neurological examination, and genetic testing. Genetic testing can confirm the presence of mutations in the GAD1 gene. Additionally, measurements of glutamate and GABA levels in the cerebrospinal fluid (CSF) may also support the diagnosis.

Treatment

There is no cure for Glutamate Decarboxylase Deficiency, and treatment is symptomatic and supportive. Management strategies may include anticonvulsant medications to control seizures and interventions aimed at supporting developmental and motor skills. In some cases, treatments that increase GABA levels in the brain, such as GABA agonists or GABA-transaminase inhibitors, may be beneficial.

Prognosis

The prognosis for individuals with Glutamate Decarboxylase Deficiency varies depending on the severity of symptoms and the effectiveness of management strategies. Early diagnosis and intervention can improve the quality of life for some individuals.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian